Regeneron Pharmaceuticals Director Files Form 144 to Sell $7.22M in Common Stock
REGENERON PHARMACEUTICALS, INC.
Subscribe to track REGN
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
{"title": "Regeneron Pharmaceuticals, Inc. (REGN) - Form 144 Filing", "description": "Director Huda Zoghbi has filed a Form 144 notice of proposed sale for 7,439 shares of Common Stock valued at approximately $7,219,263.", "fields": [{"name": "Insider", "value": "Huda Zoghbi (Director)", "inline": true}, {"name": "Proposed Sale Value", "value": "$7,219,262.83", "inline": true}, {"name": "Shares to be Sold", "value": "7,439", "inline": true}, {"name": "Estimated Price / Share", "value": "~$970.46", "inline": true}, {"name": "Approximate Sale Date", "value": "11/03/2026", "inline": true}, {"name": "Acquisition Details", "value": "Stock option exercise on 11/03/2026", "inline": false}], "color": 15105570}
Comprehensive Analysis
Executive Summary
On November 3, 2026, Huda Zoghbi, a Director of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), filed a Form 144 proposing the sale of 7,439 shares of common stock with an aggregate market value of approximately $7.22 million through UBS Financial Services Inc.
Transaction Breakdown
- Security: Common Stock
- Shares to be Sold: 7,439
- Aggregate Market Value: $7,219,262.83 (implied price of ~$970.46 per share)
- Shares Outstanding: 101,630,713 (<0.01% of outstanding shares)
- Nature of Acquisition: Acquired on November 3, 2026, via stock option exercise from the company paid in cash.
- Past 3 Months Activity: The insider previously sold 800 shares on August 10, 2026, generating gross proceeds of $640,000.
Market and Trading Context
This transaction represents an exercise-and-sell pattern common among board directors monetizing vested equity compensation. While the dollar amount is significant at $7.22M, the sale accounts for a negligible fraction of Regeneron's total share count and appears routine in nature.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.